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Abstract
Hepatitis C virus (HCV) has six well‐known genotypes in worldwide and has a very high 
genetic diversity. Introduction of DAAs leads to improvement of treatment results with 
SVR rates exceeding 95%. Development of HCV treatment resistance is a problematic 
issue that needs sufficient solutions. Many hosts, viral, and drug factors are implemented 
in the process of treatment resistance. Lack of clinical trials on treatment failure leads to 
lag in development of certain consensuses for retreatment.
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1. Introduction
Chronic hepatitis C virus (HCV) infection is a major health problem all over the world. The 
global prevalence of viremic HCV infection was reestimated between 64 and 103 million 
patients [1]. Chronic HCV patients suffered a long time from the complications of their dis‐
ease until the first discovery of interferon treatment. However, its modest response rate and 
the development of many adverse events were the major problem. Soon the dream seems 
to become true with the introduction of HCV direct acting antivirals (DAAs) in 2014. Their 
higher rates of response and minimally observed adverse events encourage more patients to 
go for treatment. In addition, patients with advanced fibrosis and cirrhosis find a new hope 
to stop the progression of their disease. Three classes of DAAs (protease inhibitors, NS5A 
inhibitors, and polymerase inhibitors) targeting three HCV enzymatic nonstructural proteins 
were approved for treatment in many countries [2]. Variability of treatment efficacy among 
patients makes it difficult to control the infection; while for some patients, weak antivirals and 
short‐term treatments are sufficient, others require combination therapies with several highly 
active antivirals for longer durations [3].
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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Despite the high rates of virological cure achieved with these treatments, the infection is not 
eliminated from a substantial number of patients (1–15%, depending on the patient status and 
regimen used) [4]. Patients and researchers started to face the new problem of drug resistance. 
In this review, HCV treatment failure in the era of DAAs will be discussed in the context of 
factors affecting development of resistance, diagnosis, and management.
2. Treatment from interferon to DAAs
Hepatitis C virus (HCV) has six well‐known genotypes in worldwide [5–10] with multiple 
subtypes (a, b, c, etc.). RNA sequence may vary by 35% between different genotypes. HCV 
has a very high genetic diversity and very high rate of replication (>10 trillion virions/day), 
and due to this replication rate, significant genetic errors occur and a continuous process of 
correction is already running to optimize the replication and sequencing of the virus genes; 
failure of error correction leads to the formation of genetic drifts [5]; these drifts are repre‐
sented either in the form of genotypes or quasispecies. Table 1 shows the difference among 
genotypes, subtypes, and quasispecies.
The presence of different HCV genotypes does not exhibit a major clinical implication on the nat‐
ural history of the disease and its progression, yet it has a great influence on treatment outcome. 
The best results for treatment in the past era of pegylated interferon (PegIFN) and ribavirin (RBV) 
were achieved in genotypes 2, 3 (80–90%) with less favorable results in genotypes 1, 4 (40–50%) 
and intermediate results in genotypes 5, 6 (60–70%). Failure of treatment during this era had no 
satisfactory solutions rather than retreatment using the same regimen or changing the pegylated 
interferon type (between alpha 2a and alpha 2b) or even extending the treatment duration.
Introduction of the direct acting antivirals (DAAs) in the playground of HCV treatment repre‐
sents a major challenge with the rising number of approved molecules and its coming followers 
in the pipe of production and approval as shown in Table 2, although the very high response to 
these drugs, which sometimes exceeds 95% yet its limited failure, represents a problematic issue.
DAAs permit to treat different categories of patients who could not be treated easily in the past 
due to the low efficacy and safety of pegylated interferon such as those with advanced liver dis‐
ease (CHILD‐PUGH B, C), autoimmune diseases, polymedicated patients, renal impairment, 
postorgan transplantation, etc. Implementation of larger groups to the treatment pipe leads to 
expulsion of more numbers of treatment failures asking for better solutions for retreatment.
Genotypes, subtypes Quasispecies
Difference in RNA sequence Mutation during replication
Major genetic differences Minor genetic differences
Does not change Continue to evolve over time
Table 1. Differences between genotypes, subtypes, and quasispecies.
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All the previously mentioned molecules have different characteristics regarding the potency, 
genotype coverage, and barrier to resistance. Table 3 shows the characteristics of DAAs mol‐
ecules [6].
Different continental guidelines for HCV management describe different treatment regimens:
1. PegIFN‐based regimens (e.g., PegIFN + RBV + Sofosbuvir, PegIFN+RBV + Simeprevir, 
PegIFN + RBV + Daclatasvir)
2. PegIFN‐free sofosbuvir‐based regimens ± ribavirin (Sofosbuvir + Daclatasvir, Sofosbuvir + 
Simeprevir, Sofosbuvir + Ledipasvir, Sofosbuvir + Velpatasvir)
3. PegIFN‐free Sofosbuvir‐free regimens ± ribavirin (Paritaprevir/r + Ombitasvir ± Dasabuvir, 
Grazoprevir + Elbasvir)
Agent class Generation Compound Phase of clinical 
development
NS3‐4A protease inhibitors First‐wave
First‐generation
Telaprevir
Boceprevir
Approved
Second‐wave
First‐generation
Simeprevir
Paritaprevir/ritonavir
Approved
Asunaprevir
Vaniprevir
Sovaprevir
In clinical development
Second‐generation Grazoprevir Approved
ACH‐2684 In clinical development
Nucleoside/nucleotide 
analogues
Nucleotide analogues Sofosbuvir Approved
MK‐3682
ACH‐3422
AL‐335
In clinical development
Nonnucleoside inhibitors Palm domain I inhibitors Dasabuvir Approved
Thumb domain I inhibitors Beclabuvir In clinical development
Thumb domain II 
inhibitors
GS‐9669 In clinical development
NS5A inhibitors First‐generation Daclatasvir
Ledipasvir
Ombitasvir
Approved
Second‐generation Elbasvir
Velpatasvir
Approved
ACH‐3102 In clinical development
Table 2. DAAa pipeline current situation (April 2016).
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3. Definitions
The terms RAVs, RASs, resistant variants, and sensitive variants were recently used in clinical 
practice to describe the susceptibility to an administered DAA. Using these definitions paved 
the way to understand more about HCV treatment failure when using DAAs. Pawlotsky has 
described well these terms as mentioned below [4]:
3.1. Viral resistance
Positive selection of viral variants with reduced susceptibility to an administered DAA.
3.2. Resistance‐associated variant (RAV)
It is often used to indifferently describe the amino acid substitutions that reduce the sus‐
ceptibility of a virus to a drug or drug class or, alternatively, the viral variants with reduced 
susceptibility that carry these substitutions.
3.3. Resistance‐associated substitutions (RASs)
The amino acid substitutions that confer resistance.
3.4. Resistant variants
The viral variants carrying these RASs and thereby have reduced susceptibility to the DAA.
3.5. Sensitive variants
Viral variants that do not contain amino acids that confer reduced susceptibility to the antiviral 
action of an HCV DAA (contain only the original wild‐type amino acids of the viral strains).
3.6. Fitness‐associated substitution(s)
Single amino acid changes that do not alter DAA susceptibility but increase the power of 
replication (fitness of the resistant variants).
Drug group Potency Genotype coverage Resistance barrier
NS3‐4A protease inhibitors +++ +++ ++
NS5A inhibitors +++ +++ ++
Nucleoside/nucleotide 
analogues
+++ +++ +++
Nonnucleoside inhibitors ++ + +
Table 3. Characteristics of DAAs molecules.
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Prior to therapy, multiple baseline HCV resistant‐associated variants (RAVs) are already 
present but usually at a very low undetectable limit. After treatment with DAAs, a sharp 
decline of HCV viremia occurs within the first treatment days and a competition between 
sensitive variants and resistant variants will determine which of the following scenarios will 
be encountered after stoppage of the administered drug:
(1) The drugs success to eliminate both sensitive and resistant variants and the patient suc‐
ceed to achieve sustained virologic response (SVR).
(2) The drug eliminates the HCV sensitive variants and rendering the resistant variants and 
after stoppage of treatment both resistant and sensitive variants are restored to the same 
baseline picture and continue to replicate.
(3) The drug eliminates the HCV sensitive variants and rendering the resistant variants and 
after stoppage of treatment the resistant variants replicate as a dominant virus.
4. Factors affecting the outcome and HCV resistance
Failure of treatment and development of resistance are a multifactorial process depending 
on host‐related factors, virus‐related factors, and drug‐related factors as shown in Figure 1.
4.1. Host‐related factors
Introduction of DAAs eliminates multiple host factors, which affect previous treatment with 
PegIFN and ribavirin, yet several host factors still persist:
Figure 1. Factors affecting treatment outcome and development of resistance.
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(1) Adherence to therapy: achievement of the best drug response surely will be better in case 
of proper administration of the drug with its proper dose at regular times and respect of 
food relations as recommended by the manufacturer.
(2) HIV, post‐organ transplantation and polymedicated patients: revision of the drug‐drug 
interactions map is necessary in those patients to avoid the effect of other drugs in reduc‐
ing the plasma level of anti‐HCV drugs.
(3) Treatment status: most of clinical trials on DAAs showed mild better response in treat‐
ment naïve patients than those who previously failed treatment with PegIFN/RBV.
(4) Hepatic fibrosis stage: patients with advanced fibrosis stage remain the most difficult to treat 
group even under the umbrella of DAAs which showed a wide variable results in cirrhotics 
ranged between 33 and 100% [7]. Addition of ribavirin and prolonged treatment duration 
may offer the best chance for those patients in achieving sustained virological response.
4.2. Virus‐related factors
(1) Genotype: treatment with PegIFN/RBV/Sofosbuvir represents the regimen that showed 
remarkable potency against all HCV genotypes. IFN‐free regimens should be selected pri‐
marily based on genotype as we have pangenotypic regimens (Sofosbuvir + Velpatasvir 
± RBV, Sofosbuvir + Daclatasvir ± RBV, Paritaprevir‐ritonavir/Ombitasvir ± Dasabuvir ± 
RBV), regimens fit for all genotypes except genotype 3 (Sofosbuvir + Simeprevir ± RBV, 
Sofosbuvir + Ledipasvir ± RBV), and individualized regimens for genotypes 2‐3‐4 (Sofos‐
buvir + RBV).
(2) Baseline RAVs: The presence of baseline RAVs seems to be associated with variable degrees 
of treatment response. Zeuzem et al. [8], observed no significant difference in response in 
noncirrhotic genotype 1 patients treated with Sofosbuvir and ledipasvir between those 
with baseline RAVs and others without RAVs in different treatment status and durations 
(98% in RAVs group vs. 99% in no RAVs group in naïve patients treated for 8 weeks, 99% in 
RAVs group vs. 99% in no RAVs group in naïve patients treated for 12 weeks, 90% in RAVs 
group vs. 99% in no RAVs group in experienced patients treated for 12 weeks). However, 
a significant difference was observed in cirrhotic patients (88% in RAVs group vs. 100% in 
no RAVs group in naïve patients treated for 24 weeks, 87% in RAVs group vs. 100% in no 
RAVs group in experienced patients treated for 24 weeks) [4]. In C‐EDGE study, Zeuzem 
et al. showed a great influence of baseline RAVs on treatment outcome in HCV GT1 pa‐
tients treated with grazoprevir/elbasvir combined with very low SVR (22%) in GT1a pa‐
tients with NS5A baseline RAVs > fivefolds potency loss [9]. No effect on SVR in genotype 
1 HCV patients with or without cirrhosis with baseline RAVs treated with combination of 
ombitasvir, r‐paritaprevir, and dasabuvir, with or without ribavirin, for 12 or 24 weeks in 
four phase three clinical trials [11]. When Sofosbuvir/Daclatasvir combination was used, 
the presence of NS5A baseline RAVs is associated with reduced rates of SVR in under‐
treated (too short duration, no ribavirin) patients with cirrhosis and genotype 3 infection 
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[12]. In addition, the presence of NS3 protease RAS Q80K was associated with a reduced 
rate of SVR in patients with HCV genotype 1a infection and cirrhosis, especially if they 
failed to respond to previous pegylated IFN–based treatment [13, 14].
4.3. Drugs‐related factors
(1) Potency and genetic barrier: the ideal drug for HCV treatment is not only potent but also 
could keep this potency against all HCV strains until cure which is known as resistant 
barrier (Table 3).
(2) Drugs combinations: lessons learned from HIV and TB management of drug resistance, 
multiple drug resistance and extensive drug resistance, outlining the frame of HCV treat‐
ment. Using multiple potent drugs for ideal durations is the best way to achieve HCV cure.
(3) Posttreatment RAVs: emergence of posttreatment RAVs has a major impact on retreat‐
ment decision. NS3‐4a RAVs appearing after treatment failure usually persists for short 
durations (12–18 months) posttreatment [10] while longer durations were observed in 
NS5A RAVs which sometimes persist for years [4, 15]. On the other hand, appearance of 
RAVs to Nucleoside/nucleotide analogues is extremely rare, and if happened, it is usu‐
ally nonreplicative [16]. Tables 4–6 show the different amino acid variants causing either 
resistance or cross‐resistance in different DAAs classes.
Variant Boceprevir Telaprevir Simeprevir Paritaprevir
V36 R R ‐ S
T54 R R ‐ ‐
V55 R ‐ ‐ S
V107 S ‐ ‐ ‐
R155 R R R S
A156 R R ‐ ‐
V158 S ‐ ‐ ‐
D168 S S R R
I/V 170 R ‐ R ‐
M175 S ‐ ‐ ‐
I132 ‐ S ‐ ‐
Q80 ‐ ‐ R ‐
S122 ‐ ‐ R ‐
Y56 ‐ ‐ ‐ R
Table 4. Resistance and cross‐resistance in NS3‐4A protease inhibitors.
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Variant Sofosbuvir Dasabuvir
S282T R R
A421V ‐ R
P495S/Q/L/A/T ‐ R
C316Y/N ‐ R
L419S ‐ R
S368T ‐ R
R422K ‐ R
M414T/I/V/L ‐ R
M423T/I/V/L ‐ R
Y448C/H ‐ R
I482L/V/T ‐ R
G554D/S ‐ R
A486/V/I/T/M ‐ R
S556G ‐ R
V494A ‐ R
D559G ‐ R
Table 6. Resistance in NS5B inhibitors.
Variant Daclatasvir Ledipasvir Ombitasvir Elbasvir Velpatasvir
M/L/L28 R ‐ ‐ ‐ ‐
P29 S ‐ ‐ ‐ ‐
Q/R/L30 R ‐ ‐ ‐ ‐
L31 R R ‐ R ‐
P32 S ‐ ‐ ‐ ‐
H/P58 R ‐ ‐ ‐ ‐
E62 S ‐ ‐ ‐ ‐
A92 S ‐ ‐ ‐ ‐
Y93 R R R R R
M28 ‐ S R R ‐
Q30 ‐ R R R ‐
H58 ‐ S S ‐ ‐
M/L28 ‐ ‐ R ‐
Table 5. Resistance and cross‐resistance in NS5A inhibitors.
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5. Diagnosis of HCV RAVs
5.1. Diagnosis of resistance in clinical practice is conducted by two methods
(1) Phenotypic analysis: used to determine the optimum plasma concentration (effective con‐
centration, EC
50
 EC
90
) of the dug sufficient to inhibit the viral replication.
RAVs are typically associated with a change in the shape of the binding or interaction site 
of DAAs to HCV target proteins. RAVs harbor different levels of resistance due to dif‐
ferent locations within the sites of interaction and different chemical structures of DAAs 
targeting the same site on the same HCV protein [3].
(2) Genotypic analysis (sequence analysis): used to detect the amino acids substitutes which 
cause drug resistance and treatment failure [17]. Clonal and deep sequencing technologies 
allow reliable detection of viral variants with a frequency down to 0.5–1% and commonly 
accepted level reached to 15% [18]. Generally, due to the high heterogeneity of HCV iso‐
lates and methodological restrictions all sequencing technologies may miss detection of 
RAVs due to nonamplification based on HCV RNA secondary structures, primer selec‐
tion, and low frequencies within HCV quasispecies [3].
Resistance testing in clinical practice is not so easy, but it is actually very difficult. Limited 
number of well‐equipped virological labs all over the world that can deal with these tests, 
experienced hands and the ability to interpret the results correctly, make testing for resistance 
a time and money consuming procedure and balancing the benefit versus the cost should be 
considered especially when dealing with large populations having different genotypes.
5.2. Timing of HCV resistance testing
Because of the above‐mentioned limitations, resistance testing is not recommended before start‐
ing therapy with DAAs for the first time; especially in areas where HCV is highly endemic. 
Instead, trying to give patients the best chance of cure through using multiple drugs, adding rib‐
avirin or prolongation of the treatment duration if needed may be a good decision; also testing at 
the time of treatment failure usually associated with high prevalence of quasispecies and RAVs.
On the other hand, testing of resistance before retreatment of patients who fail to achieve 
virological response with DAAs may have a benefit for the proper selection of the best DAA 
drug for retreatment [4].
6. Management of drug failure and drug resistance
Clear evidence is still not available about the best regimens, best duration, and best time for 
retreatment of patients with DAAs failures, yet European association for the study of the 
liver (EASL) [19] and American association for the study of the liver diseases (AASLD) [20] 
released their interim opinions for retreatment options.
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EASL guidelines recommend that Sofosbuvir should be a cornerstone in any retreatment trial 
due to its high barrier to resistance, addition of 1 or 2 other DAAs preferably with no cross‐
resistance with the failed drug, addition of ribavirin if tolerable and prolongation of treatment 
duration to 24 weeks especially in cirrhotics.
AASLD guidelines using Sofosbuvir‐based triple or quadruple DAAs with ribavirin if toler‐
able for 12–24 weeks in case of failure of Sofosbuvir‐based dual regimen, RAVs testing prior 
to retreatment and the final treatment options is tailored based on its results.
Review of some recent published data in Table 7 for retreatment of clinical trials appears to 
be insufficient to justify a competent guidelines, more data is needed to reach to the nearest 
figure to ideal. From these trials, we could choose one of the following models:
(1) The patients have no RAVs, so retreatment using the same failed regimen (or adding other 
drugs) could be allowed but add ribavirin if needed but not previously added and choose 
the ideal duration according to the patient status.
(2) The patient has RAVs to protease or polymerase inhibitors, which will disappear after 
few weeks or months, so we could choose either to wait until reset point or to use another 
family of DAAs like NS5A inhibitors plus sofosbuvir.
(3) The patient has RAVs to NS5A inhibitor drug without cross‐resistance, so the failed drug 
could not be used but other drugs from the same family could be.
(4) The patient has RAVs to NS5A inhibitor at certain sites leading to resistance and cross‐
resistance, so the whole NS5A members from the same wave could not be used, shifting 
to different wave of the family or changing the whole group to protease inhibitors will 
be the best way.
Description Retreatment regimen Results RAVs impact
Wyles et al. [21] 51 GT1 patients with 
previous treatment failure
25 patients failed PegIFN/
RBV/Sofosbuvir
20 patients failed 
Sofosbuvir/RBV
5 failed Sofosbuvir placebo/
PegIFN/RBV
1 failed GS‐0938 
monotherapy
Sofosbuvir + 
Ledipasvir + 
Ribavirin for 12 
weeks
50/51 (98%) SVR NA
Forns et al. [22] 79 GT1 patients with 
previous treatment failure
66 patients failed PegIFN/
RBV/protease inhibitor
12 patients intolerable to 
treatment with PegIFN/
RBV/protease inhibitor
Grazoprevir + 
Elbasvir + Ribavirin 
for 12 weeks
76/79(96.2%) 
SVR
‐100% in patients 
without baseline RAVs
‐91.2% with baseline 
NS3 RAVs
‐75% with baseline 
NS5A RAVs
‐66.7% in both NS3, 
NS5A RAVs
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7. Conclusion
HCV elimination is a worldwide goal; curing infection with oral drugs for short duration and 
minimal adverse events is going on. Appearance of resistance to DAAs is disappointing to the 
clinicians and the researchers yet choosing the proper treatment regimen initially leading to 
minimizing this problem. The ideal RAVs testing and interpretation lead to the best options 
to justify the retreatment regimen.
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Description Retreatment regimen Results RAVs impact
Hézode et al. [23] Real world data
16 GT1, 4 patients with 
previous treatment failure
13 patients failed PegIFN/
RBV/daclatsvir/asunaprevir
3 patients failed PegIFN/
RBV/daclatasvir
Sofosbuvir + 
Simeprevir for 12 
weeks without 
ribavirin
14/16 (87.5%) 
SVR
Presence of Simeprevir 
RAVs (R155K and 
Q80K) had no effect on 
treatment outcome
Lawitz et al., 
C‐SWIFT [24]
25 GT1 patients failed 
Grazoprevir + Elbasvir + 
Sofosbuvir for 4, 6, or 8 
weeks
Grazoprevir + 
Elbasvir + Sofosbuvir 
+ RBV for 12 weeks
100% SVR No impact
Poordad et al. 
QUARTZ 1 [25]
22 GT1 patients with 
previous treatment failure 
to DAAs
14 patients to OBV/PTV/r 
+ DSV
2 patients to OBV/PTV/r
2 patients to telaprevir
2 patients to SOF
1 patient to simeprevir/
samatasvir 1 patient to 
simeprevir + SOF
‐OBV/PTV/r + DSV 
+ SOF for 12 weeks 
in patients without 
cirrhosis
‐OBV/PTV/r + DSV 
+ SOF + RBV for 
12 weeks in GT1a 
patients without 
cirrhosis
‐OBV/PTV/r + 
DSV + SOF + RBV 
for 24 weeks in 
GT1a patients with 
cirrhosis
14/15 (93%) SVR 
12 IN
patients treated 
for 12 weeks, 7/7 
(100 %) SVR 4 in 
patients
received 24 
weeks
No impact
Table 7. Review of recent data for retreatment.
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